Manhattan Bridge Capital, Inc. Reports Third Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Manhattan Bridge Capital, Inc. Reports Third Quarter Results

LONG ISLAND, NY--(Marketwired - Oct 26, 2016) - Manhattan Bridge Capital, Inc. ( NASDAQ : LOAN ) announced today that total revenue for the three month period ended September 30, 2016 was approximately $1,169,000 compared to approximately $1,032,000 for the three month period ended September 30, 2015, an increase of $137,000, or 13.3%. The increase in revenue represents an increase in lending operations. For the three month periods ended September 30, 2016 and 2015, approximately $960,000 and $871,000, respectively, of our revenues were attributable to interest income on the secured commercial loans that we offer to small businesses, and approximately $209,000 and $160,000, respectively, of our revenues were attributable to origination fees on such loans.

Net income for the three month period ended September 30, 2016 was approximately $725,000 or $0.10 per basic and diluted share, versus net income of approximately $639,000 or $0.09 per basic and diluted share for the three month period ended September 30, 2015, an increase of $86,000 or 13.5%. This increase in net income was mainly due to an increase in operating income as a result of increased lending activity.

Total revenue for the nine month period ended September 30, 2016 was approximately $3,440,000 compared to approximately $2,855,000 for the nine month period ended September 30, 2015, an increase of $585,000, or 20.5%. The increase in revenue represents an increase in lending operations. For the nine month periods ended September 30, 2016 and 2015, revenues of approximately $2,849,000 and $2,392,000, respectively, were attributable to interest income on the secured commercial loans that we offer to small businesses, and approximately $591,000 and $463,000, respectively, were attributable to origination fees on such loans.

Net income for the nine month period ended September 30, 2016 was approximately $2,130,000 or $0.29 per basic and diluted share, versus net income of approximately $1,645,000 or $0.25 per basic and diluted share for the same period in 2015, an increase of $485,000 or 29.5%. This increase in net income was mainly due to an increase in operating income as a result of increased lending activity.

As of September 30, 2016 total shareholders' equity was approximately $23,125,000 compared to approximately $18,638,000 as of June 30, 2016 and approximately $17,743,000 as of December 31, 2015.

On August 15, 2016, we completed another public offering of 672,269 common shares. In addition, the underwriter fully exercised its over-allotment option for an additional 100,840 common shares. The gross proceeds from the offering, including the exercise of the over-allotment option, were approximately $4.6 million and the net proceeds were approximately $4.2 million, after deducting our underwriting discounts and commissions and offering expenses.

Assaf Ran, Chairman of the Board and CEO stated, "I am pleased with the results that we have reported for the quarter. In light of what I believe is presently a relatively risky and unstable real estate market climate, our challenge, more than ever, is to cherry-pick the safest lending opportunities. We have successfully achieved another record quarter on both revenue and net earnings while continuing our no-default track record."

About Manhattan Bridge Capital, Inc. Manhattan Bridge Capital, Inc. offers short-term secured, non-banking loans (sometimes referred to as "hard money" loans) to real estate investors to fund their acquisition, renovation, rehabilitation or improvement of properties located in the New York metropolitan area. We operate the web site: http://www.manhattanbridgecapital.com

This report contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are typically identified by the words "believe," "expect," "intend," "estimate" and similar expressions. Those statements appear in a number of places in this report and include statements regarding our intent, belief or current expectations or those of our directors or officers with respect to, among other things, trends affecting our financial condition and results of operations and our business and growth strategies. These forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors (such factors are referred to herein as "Cautionary Statements"), including but not limited to the following: (i) we have limited operating history as a REIT; (ii) our loan origination activities, revenues and profits are limited by available funds (iii)we operate in a highly competitive market and competition may limit our ability to originate loans with favorable interest rates; (iv) our chief executive officer is critical to our business and our future success may depend on our ability to retain him; (v) if we overestimate the yields on our loans or incorrectly value the collateral securing the loan, we may experience losses; (vi) we may be subject to "lender liability" claims; (vii) our loan portfolio is illiquid; (viii) our due diligence may not uncover all of a borrower's liabilities or other risks to its business; (ix) borrower concentration could lead to significant losses; (x) our management has no experience managing a REIT; and (xi) we may choose to make distributions in our own stock, in which case you may be required to pay income taxes in excess of the cash dividends you receive. The accompanying information contained in this report, including the information set forth under "Management's Discussion and Analysis of Financial Condition and Results of Operations", identifies important factors that could cause such differences. These forward-looking statements speak only as of the date of this report, and we caution potential investors not to place undue reliance on such statements. We undertake no obligation to update or revise any forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the Cautionary Statements.

 
 
MANHATTAN BRIDGE CAPITAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
 
Assets   September 30, 2016 (unaudited)   December 31, 2015 (audited)
Current assets:            
Cash and cash equivalents   $ 158,519   $ 106,836
Cash - restricted     919,352     ---
Short term loans receivable     23,314,500     20,199,000
Interest receivable on loans     304,338     382,572
Other current assets     49,673     32,865
    Total current assets     24,746,382     20,721,273
             
Long term loans receivable     8,217,320     10,705,040
Property and equipment, net     9,038     8,771
Security deposit     6,816     6,816
Investment in privately held company     40,000     50,000
Deferred financing costs     68,234     164,510
    Total assets   $ 33,087,790   $ 31,656,410
   
Liabilities and Stockholders' Equity  
Current liabilities:                
Line of credit   $ 4,263,055     $ 11,821,099  
Short term loans     ---       1,095,620  
Accounts payable and accrued expenses     71,940       99,643  
Deferred origination fees     344,561       279,682  
Dividends payable     ---       617,443  
  Total current liabilities     4,679,556       13,913,487  
Long term liabilities:                
Senior secured note (net of deferred financing costs of $716,441)      5,283,559        ---  
    Total liabilities     9,963,115       13,913,487  
Commitments and contingencies                
Stockholders' equity:                
Preferred shares - $.01 par value; 5,000,000 shares authorized; no shares issued      ---        ---  
Common shares - $.001 par value; 25,000,000 authorized; 8,290,749 and 7,441,039 issued; 8,113,749 and 7,264,039 outstanding     8,291       7,441  
Additional paid-in capital     23,025,856       18,500,524  
Treasury stock, at cost - 177,000     (369,335 )     (369,335 )
Retained earnings (Accumulated deficit)     459,863       (395,707 )
  Total stockholders' equity     23,124,675       17,742,923  
Total liabilities and stockholders' equity   $ 33,087,790     $ 31,656,410  
   
   
MANHATTAN BRIDGE CAPITAL, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(unaudited)  
   
    Three Months Ended September 30 ,     Nine Months Ended September 30 ,  
    2016   2015     2016     2015  
Interest income from loans   $ 960,274   $ 871,250     $ 2,848,516     $ 2,392,329  
Origination fees     208,951     160,456       591,191       463,092  
  Total revenue     1,169,225     1,031,706       3,439,707       2,855,421  
                               
Operating costs and expenses:                              
Interest and amortization of debt service costs     205,449     159,875       593,749       493,652  
Referral fees     2,263     948       5,525       3,260  
General and administrative expenses     236,972     229,873       698,356       696,464  
  Total operating costs and expenses     444,684     390,696       1,297,630       1,193,376  
Income from operations     724,541     641,010       2,142,077       1,662,045  
Loss on write-down of investment in privately held company     ---     ---       (10,000 )     (15,000 )
Income before income tax expense     724,541     641,010       2,132,077       1,647,045  
Income tax expense     ---     (2,005 )     (2,146 )     (2,005 )
Net income   $ 724,541   $ 639,005     $ 2,129,931     $ 1,645,040  
                               
Basic and diluted net income per common share outstanding:                              
--Basic   $ 0.10   $ 0.09     $ 0.29     $ 0.25  
--Diluted   $ 0.10   $ 0.09     $ 0.29     $ 0.25  
                               
Weighted average number of common shares outstanding                              
--Basic     7,598,626     7,223,043       7,407,787       6,597,987  
--Diluted     7,623,635     7,263,017       7,426,165       6,637,755  
 
 
MANHATTAN BRIDGE CAPITAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
    Nine Months  
    Ended September 30,  
    2016     2015  
Cash flows from operating activities:                
  Net Income   $ 2,129,931     $ 1,645,040  
  Adjustments to reconcile net income to net cash provided by operating activities -                
  Amortization of deferred financing costs     51,474       27,501  
  Depreciation     2,752       4,926  
  Non cash compensation expense     10,192       10,248  
  Loss on write-down of investment in privately held company     10,000       15,000  
  Changes in operating assets and liabilities:                
    Interest receivable on loans     78,234       (108,815 )
    Other current and non current assets     (16,809 )     (27,377 )
    Accounts payable and accrued expenses     (27,702 )     (74,031 )
    Deferred origination fees     64,879       4,360  
      Net cash provided by operating activities     2,302,951       1,496,852  
                 
Cash flows from investing activities:                
  Issuance of short term loans     (24,299,500 )     (15,346,500 )
  Collections received from loans     23,671,720       10,234,936  
  Purchase of fixed assets     (3,019 )     (3,474 )
      Net cash used in investing activities     (630,799 )     (5,115,038 )
                 
Cash flows from financing activities:                
  (Repayments of) Proceeds from loans and line of credit, net     (8,653,664 )     1,024,238  
  Cash restricted for reduction of line of credit     (919,352 )     ---  
  Proceeds from public offerings, net     9,539,347       4,237,199  
  Deferred financing costs     ---       (111,400 )
  Proceeds from exercise of stock options and warrants     305,004       32,838  
  Dividends paid     (1,891,804 )     (1,551,221 )
      Net cash (used in) provided by financing activities     (1,620,469 )     3,631,654  
                 
Net increase in cash and cash equivalents     51,683       13,468  
Cash and cash equivalents, beginning of period     106,836       47,676  
Cash and cash equivalents, end of period   $ 158,519     $ 61,144  
                 
Supplemental Cash Flow Information:                
Taxes paid during the period   $ 1,948     $ 29  
Interest paid during the period   $ 546,015     $ 423,650  

Contact: Assaf Ran CEO Vanessa Kao CFO (516) 444-3400

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 956

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 251

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 295

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 471

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 245

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 307

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 597

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading

Top 5 Most Recently Viewed Articles

Explore Consciousness at the CONTACT Modalities XPO Gathering

Updated Category News Views 271

CONTACT Modalities XPO: A Unique Gathering for Consciousness Exploration Prepare to embark on a transformative journey of self-discovery and exploration at the CONTACT Modalities XPO. This gathering promises to bring together passionate individuals eager to delve into consciousness studies through engaging sessions and workshops. The event will be held at the stunning...

Continue Reading
Green Thumb Industries Set to Unveil Q3 2025 Financial Overview

Updated Category News Views 266

Green Thumb Industries to Report Third Quarter Financial Results Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), a standout in the cannabis consumer packaged goods sector, is poised to unveil its financial performance for the third quarter of 2025. The eagerly anticipated announcement will occur after market hours on November 5, 2025. Known for its growth and...

Continue Reading
Boussard & Gavaudan Holding: Estimated NAV Update

Updated Category News Views 129

About Boussard & Gavaudan Holding Limited Boussard & Gavaudan Holding Limited aims to keep shareholders informed—plain and simple. The company provides timely updates on its estimated net asset values (NAVs) and on the performance of its Euro and Sterling share classes, so you can track what matters without guesswork. How the Estimated NAV Is Determined Each month, the...

Continue Reading
Booming Yacht Rental Market Set to Surpass $13 Billion Milestone

Updated Category News Views 93

The yacht rental market hit a turning point, projected to exceed $13.1 billion in value—back when those forecasts came out, traders were buzzing about it. The allure of luxury travel had folks flocking to yacht rentals like moths to a flame. Market Drivers: Luxury Demand or Overhyped? High-net-worth individuals fueled the demand for yacht rentals, as they sought...

Continue Reading
Hellenic Telecom Completes Share Repurchase, Strengthening Value

Updated Category News Views 156

Hellenic Telecom's Successful Share Buyback Program Hellenic Telecommunications Organization S.A. (ATH:HTO), widely recognized as OTE, has recently finished a significant week of share repurchasing. In a strategic move, the company acquired a total of 414,128 shares, investing approximately €6.16 million at an average price of €14.87 per share. Understanding the Share...

Continue Reading